{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:17:01Z","timestamp":1781619421863,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Korean Society of Inherited Metabolic Disease","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Phenylketonuria (PKU) is an inherited metabolic disorder caused by mutations in the phenylalanine hydroxylase (\n                    <jats:italic>PAH<\/jats:italic>\n                    ) gene, leading to phenylalanine accumulation and clinical symptoms such as intellectual disability and hypopigmentation. Histone deacetylase 6 inhibitors (HDAC6i), known to promote the degradation of misfolded proteins, have shown potential in treating protein misfolding-related disorders. In this study, we evaluated the therapeutic effect of Tubastatin A, a selective HDAC6i, in\n                    <jats:italic>Pah<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>eun2<\/jats:italic>\n                    <\/jats:sup>\n                    PKU model mice carrying a missense PAH mutation. Mice were treated with Tubastatin A for 12 weeks, and outcomes were assessed via phenylalanine levels, fur pigmentation, and expression of heat shock protein 90 (HSP90). Treated mice exhibited approximately a 50% reduction in plasma phenylalanine levels, partial recovery of black fur pigmentation, and increased expression of acetylated HSP90 in the liver. These findings suggest that HDAC6 inhibition may alleviate PKU symptoms by increasing HSP90 acetylation, which interferes with the degradation of misfolded PAH and may allow residual enzymatic activity. Our results support the therapeutic potential of HDAC6i in PKU and warrant further studies to optimize dosage and evaluate the long-term effects and safety of sustained treatment.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-29143-7","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T13:52:50Z","timestamp":1763819570000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic effect of histone deacetylase 6 inhibitor for a mouse model of phenylketonuria"],"prefix":"10.1038","volume":"15","author":[{"given":"Jung Eun","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeyoung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeryung","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Il Tae","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Chul","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae Soon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,22]]},"reference":[{"issue":"9750","key":"29143_CR1","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(10)60961-0","volume":"376","author":"N Blau","year":"2010","unstructured":"Blau, N., van Spronsen, F. J. & Levy, H. L. Phenylketonuria Lancet ;376(9750):1417\u20131427. (2010).","journal-title":"Phenylketonuria Lancet"},{"issue":"4","key":"29143_CR2","first-page":"304","volume":"4","author":"N Al Hafid","year":"2015","unstructured":"Al Hafid, N. & Christodoulou, J. Phenylketonuria: a review of current and future treatments. Transl Pediatr. 4 (4), 304\u2013331 (2015).","journal-title":"Transl Pediatr."},{"issue":"2","key":"29143_CR3","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1203\/01.PDR.0000132837.29067.0E","volume":"56","author":"HJ Oh","year":"2004","unstructured":"Oh, H. J., Park, E. S., Kang, S., Jo, I. & Jung, S. C. Long-Term enzymatic and phenotypic correction in the phenylketonuria mouse model by Adeno-Associated virus Vector-Mediated gene transfer. Pediatr. Res. 56 (2), 278\u2013284 (2004).","journal-title":"Pediatr. Res."},{"key":"29143_CR4","unstructured":"Scriver, C. R., Kaufman, S., Eisensmith, R. C. & Woo, S. L. The Metabolic and Molecular Bases of Inherited Disease 8th edn, 1667\u20131724 (McGraw Hill, 2001)."},{"issue":"1","key":"29143_CR5","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13023-017-0685-2","volume":"12","author":"AMJ van Wegberg","year":"2017","unstructured":"van Wegberg, A. M. J. et al. The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet J. Rare Dis. 12 (1), 162 (2017).","journal-title":"Orphanet J. Rare Dis."},{"issue":"2","key":"29143_CR6","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/gim.2013.157","volume":"16","author":"J Vockley","year":"2014","unstructured":"Vockley, J. et al. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet. Med. 16 (2), 188\u2013200 (2014).","journal-title":"Genet. Med."},{"key":"29143_CR7","unstructured":"van Wegberg, A. M. J. et al. European guidelines on diagnosis and treatment of phenylketonuria: First revision. Mol. Genet. Metab. 145(2), 109125 (2025)."},{"key":"29143_CR8","doi-asserted-by":"crossref","unstructured":"145:109125. European guidelines on diagnosis and treatment of phenylketonuria: First revision. Mol Genet Metab et al. Nutrient intakes and physical growth of children with phenylketonuria undergoing nutrition therapy. J Am Diet Assoc. 2003;103(9):1167\u20131173. (2025).","DOI":"10.1016\/S0002-8223(03)00983-0"},{"issue":"5","key":"29143_CR9","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s40265-019-01079-z","volume":"79","author":"U Lichter-Konecki","year":"2019","unstructured":"Lichter-Konecki, U. & Vockley, J. Phenylketonuria: current treatments and future developments. Drugs 79 (5), 495\u2013500 (2019).","journal-title":"Drugs"},{"issue":"5","key":"29143_CR10","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1086\/521879","volume":"81","author":"AL Pey","year":"2007","unstructured":"Pey, A. L., Stricher, F., Serrano, L. & Martinez, A. Predicted effects of missense mutations on native-state stability account for phenotypic outcome in phenylketonuria, a paradigm of misfolding diseases. Am. J. Hum. Genet. 81 (5), 1006\u20131024 (2007).","journal-title":"Am. J. Hum. Genet."},{"issue":"1","key":"29143_CR11","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41572-021-00267-0","volume":"7","author":"FJ van Spronsen","year":"2021","unstructured":"van Spronsen, F. J. et al. Nat. Rev. Dis. Primers ;7(1):36. (2021).","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"1","key":"29143_CR12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40246-022-00398-9","volume":"16","author":"NA Elhawary","year":"2022","unstructured":"Elhawary, N. A. et al. Genetic etiology and clinical challenges of phenylketonuria. Hum. Genomics. 16 (1), 16 (2022).","journal-title":"Hum. Genomics"},{"issue":"3","key":"29143_CR13","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ymgme.2022.01.004","volume":"135","author":"C Lin","year":"2022","unstructured":"Lin, C. et al. Importance of the long non-coding RNA (lncRNA) transcript HULC for the regulation of phenylalanine hydroxylase and treatment of phenylketonuria. Mol. Genet. Metab. 135 (3), 171\u2013178 (2022).","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"29143_CR14","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1038\/s41467-023-39246-2","volume":"14","author":"DL Brooks","year":"2023","unstructured":"Brooks, D. L. et al. Rapid and definitive treatment of phenylketonuria in variant-humanized mice with corrective editing. Nat. Commun. 14 (1), 3451 (2023).","journal-title":"Nat. Commun."},{"issue":"11","key":"29143_CR15","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1089\/hum.2019.111","volume":"30","author":"HM Grisch-Chan","year":"2019","unstructured":"Grisch-Chan, H. M., Schwank, G., Harding, C. O. & Th\u00f6ny, B. State-of-the-Art 2019 on gene therapy for phenylketonuria. Hum. Gene Ther. 30 (11), 1274\u20131283 (2019).","journal-title":"Hum. Gene Ther."},{"key":"29143_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1750-1326-8-7","volume":"8","author":"C Simoes-Pires","year":"2013","unstructured":"Simoes-Pires, C. et al. HDAC6 as a target for neurodegenerative diseases: what makes it different from the other hdacs? Mol. Neurodegener. 8, 7 (2013).","journal-title":"Mol. Neurodegener"},{"issue":"23","key":"29143_CR17","doi-asserted-by":"publisher","first-page":"5096","DOI":"10.1111\/bph.15231","volume":"27","author":"N Ha","year":"2020","unstructured":"Ha, N. et al. A novel histone deacetylase 6 inhibitor improves myelination of Schwann cells in a model of Charcot\u2013Marie\u2013Tooth disease type 1A. Br. J. Pharmacol. 27 (23), 5096\u20135113 (2020).","journal-title":"Br. J. Pharmacol."},{"issue":"48","key":"29143_CR18","doi-asserted-by":"publisher","first-page":"40282","DOI":"10.1074\/jbc.M508786200","volume":"280","author":"A Iwata","year":"2005","unstructured":"Iwata, A., Riley, B. E., Johnston, J. A. & Kopito, R. R. HDAC6 and microtubules are required for autophagic degradation of aggregated Huntingtin. J. Biol. Chem. 280 (48), 40282\u201340292 (2005).","journal-title":"J. Biol. Chem."},{"issue":"1","key":"29143_CR19","first-page":"1","volume":"20","author":"NM Jung","year":"2020","unstructured":"Jung, N. M., Nam, Y. H., Park, S. Y., Kim, J. Y. & Jung, S. C. Inhibitory action of a histone deacetylase 6 inhibitor on Glucosylceramide- and Glucosylsphingosine-induced neuronal cell apoptosis. J. Korean Soc. Inherit. Metab. Dis. 20 (1), 1\u201313 (2020).","journal-title":"J. Korean Soc. Inherit. Metab. Dis."},{"issue":"1","key":"29143_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10020-021-00375-3","volume":"27","author":"Y Liu","year":"2021","unstructured":"Liu, Y., Li, Y., Wang, X. & Liu, Y. Interplay between histone deacetylase 6 and heat-shock protein 90: implications for cancer therapy. Mol. Med. 27 (1), 1\u201315 (2021).","journal-title":"Mol. Med."},{"issue":"1","key":"29143_CR21","doi-asserted-by":"publisher","first-page":"14666","DOI":"10.1038\/s41598-024-65094-1","volume":"25","author":"N Bahram Sangani","year":"2024","unstructured":"Bahram Sangani, N. et al. A novel insight into neurological disorders through HDAC6 protein\u2013protein interactions. Sci. Rep. 25 (1), 14666 (2024).","journal-title":"Sci. Rep."},{"issue":"3","key":"29143_CR22","doi-asserted-by":"publisher","first-page":"178","DOI":"10.5483\/BMBRep.2022-0157","volume":"56","author":"E Li","year":"2023","unstructured":"Li, E. et al. A novel HDAC6 inhibitor, CKD-504, is effective in treating preclinical models of huntington\u2019s disease. BMB Rep. 56 (3), 178\u2013183 (2023).","journal-title":"BMB Rep."},{"key":"29143_CR23","first-page":"875784","volume":"2011","author":"CI Aldanan-Masankay","year":"2011","unstructured":"Aldanan-Masankay, C. I. & Sakamoto, K. M. The role of HDAC6 in cancer. J. Biomed. Biotechnol. 2011, 875784 (2011).","journal-title":"J. Biomed. Biotechnol."},{"issue":"1","key":"29143_CR24","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-018-0654-9","volume":"11","author":"T Li","year":"2018","unstructured":"Li, T. et al. Histone deacetylase 6 in cancer. J. Hematol. Oncol. 11 (1), 111 (2018).","journal-title":"J. Hematol. Oncol."},{"issue":"11","key":"29143_CR25","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.tcb.2005.09.003","volume":"15","author":"S Aoyagi","year":"2005","unstructured":"Aoyagi, S. & Archer, T. K. Modulating molecular chaperone Hsp90 functions through reversible acetylation. Trends Cell. Biol. 15 (11), 565\u2013567 (2005).","journal-title":"Trends Cell. Biol."},{"issue":"2","key":"29143_CR26","first-page":"277","volume":"23","author":"SC Jung","year":"2008","unstructured":"Jung, S. C., Park, E. S., Kang, S., Jo, I. & Oh, H. J. Protective effect of Recombinant adeno-associated virus 2\/8-mediated gene therapy from the maternal hyperphenylalaninemia in offspring of a mouse model of phenylketonuria. J. Korean Med. Sci. 23 (2), 277\u2013283 (2008).","journal-title":"J. Korean Med. Sci."},{"issue":"1","key":"29143_CR27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s10020-021-00375-3","volume":"27","author":"P Liu","year":"2021","unstructured":"Liu, P. et al. Posttranslational modification and beyond: interplay between histone deacetylase 6 and heat-shock protein 90. Mol. Med. 27 (1), 26 (2021).","journal-title":"Mol. Med."},{"issue":"6","key":"29143_CR28","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1002\/jimd.12392","volume":"44","author":"RA Kaiser","year":"2021","unstructured":"Kaiser, R. A. et al. Use of an adeno-associated virus serotype Anc80 to provide durable cure of phenylketonuria in a mouse model. J. Inherit. Metab. Dis. 44 (6), 1369\u20131381 (2021).","journal-title":"J. Inherit. Metab. Dis."},{"key":"29143_CR29","unstructured":"ClinicalTrials.gov. A Study to Evaluate the Safety and Efficacy of BMN 307 (AAV5-PAH) in Participants With Phenylketonuria (PKU). Identifier: NCT04480567. Updated June 2024. Accessed July 8. (2025). Available from: https:\/\/clinicaltrials.gov\/study\/NCT04480567"},{"issue":"7146","key":"29143_CR30","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/nature05853","volume":"447","author":"UB Pandey","year":"2007","unstructured":"Pandey, U. B. et al. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 447 (7146), 859\u2013863 (2007).","journal-title":"Nature"},{"issue":"12","key":"29143_CR31","first-page":"3342","volume":"10","author":"P Lopresti","year":"2020","unstructured":"Lopresti, P. HDAC6 in diseases of cognition and neurons. Cells 10 (12), 3342 (2020).","journal-title":"Cells"},{"issue":"3","key":"29143_CR32","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1083\/jcb.201403039","volume":"206","author":"NO Deakin","year":"2014","unstructured":"Deakin, N. O. & Turner, C. E. Paxillin inhibits HDAC6 to regulate microtubule acetylation, golgi structure, and polarized migration. J. Cell. Biol. 206 (3), 395\u2013413 (2014).","journal-title":"J. Cell. Biol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29143-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29143-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29143-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:26:33Z","timestamp":1781616393000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29143-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,22]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["29143"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-29143-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,22]]},"assertion":[{"value":"28 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44998"}}